866-997-4948(US-Canada Toll Free)

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Oct 2015

Category :

Cancer

No. of Pages : 374 Pages

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 11
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 12
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 13
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 21
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 26
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 27
AB Science SA 27
AbbVie Inc. 28
Adamis Pharmaceuticals Corporation 29
Advaxis, Inc. 30
Ambrx, Inc. 31
Amgen Inc. 32
Arrowhead Research Corporation 33
AstraZeneca Plc 34
ATLAB Pharma SAS 35
Bavarian Nordic A/S 36
BIND Therapeutics, Inc. 37
Boehringer Ingelheim GmbH 38
Bristol-Myers Squibb Company 39
CellCentric Ltd 40
CureVac GmbH 41
DexTech Medical AB 42
Eli Lilly and Company 43
Emergent BioSolutions Inc. 44
F. Hoffmann-La Roche Ltd. 45
Genentech, Inc. 46
GenSpera, Inc. 47
GlaxoSmithKline Plc 48
GTx, Inc. 49
Johnson & Johnson 50
Karyopharm Therapeutics, Inc. 51
Medivation, Inc. 52
Millennium Pharmaceuticals, Inc. 53
NewLink Genetics Corporation 54
Novartis AG 55
Oncogenex Pharmaceuticals, Inc. 56
Oncolytics Biotech Inc. 57
Onyx Pharmaceuticals, Inc. 58
Orion Oyj 59
Pfizer Inc. 60
Progenics Pharmaceuticals, Inc. 61
Sanofi 62
Sotio a.s. 63
Sun Pharma Advanced Research Company Ltd. 64
Supratek Pharma Inc. 65
Taiho Pharmaceutical Co., Ltd. 66
Takeda Pharmaceutical Company Limited 67
Tesaro, Inc. 68
Tokai Pharmaceuticals, Inc. 69
TRACON Pharmaceuticals, Inc. 70
Viralytics Ltd. 71
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 72
Assessment by Monotherapy Products 72
Assessment by Target 73
Assessment by Mechanism of Action 77
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
abiraterone acetate - Drug Profile 84
ABS-001 - Drug Profile 87
Adipotide - Drug Profile 88
ADXS-PSA - Drug Profile 89
afuresertib hydrochloride - Drug Profile 91
apatorsen - Drug Profile 93
APC-200 - Drug Profile 95
APC-300 - Drug Profile 96
ASN-001 - Drug Profile 97
ATL-101 - Drug Profile 98
AZD-5312 - Drug Profile 100
AZD-5363 - Drug Profile 101
BI-836845 - Drug Profile 103
BMTP-11 - Drug Profile 105
cabazitaxel - Drug Profile 106
cabazitaxel - Drug Profile 108
carfilzomib - Drug Profile 109
Cell Therapy to Target PSMA for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 113
crizotinib - Drug Profile 114
custirsen sodium - Drug Profile 118
CV-9103 - Drug Profile 122
CVA-21 - Drug Profile 123
Dendritic Cell Therapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 127
docetaxel - Drug Profile 128
docetaxel - Drug Profile 130
emibetuzumab - Drug Profile 131
enzalutamide - Drug Profile 132
erismodegib - Drug Profile 135
ES-414 - Drug Profile 138
everolimus - Drug Profile 139
galeterone - Drug Profile 145
GSK-2636771 - Drug Profile 147
GTx-758 - Drug Profile 148
idasanutlin - Drug Profile 150
indoximod - Drug Profile 152
JNJ-56021927 - Drug Profile 154
lirilumab - Drug Profile 156
LY-3022855 - Drug Profile 158
LY-3023414 - Drug Profile 159
masitinib - Drug Profile 161
mipsagargin - Drug Profile 166
Monoclonal Antibody Drug Conjugate to Inhibit PSMA for GBM and CRPC - Drug Profile 168
MVI-816 - Drug Profile 169
navitoclax dihydrochloride - Drug Profile 171
niraparib - Drug Profile 173
ODM-201 - Drug Profile 175
ODM-204 - Drug Profile 177
olaparib - Drug Profile 178
olaratumab - Drug Profile 182
ONC-113B - Drug Profile 184
Osteodex - Drug Profile 185
pelareorep - Drug Profile 186
Protein for Prostate Cancer - Drug Profile 191
PSMA ADC - Drug Profile 192
rilimogene galvacirepvec - Drug Profile 194
rilotumumab - Drug Profile 197
sapanisertib - Drug Profile 199
selinexor - Drug Profile 201
Small Molecule to Antagonize Androgen Receptor for Prostate Cancer - Drug Profile 207
Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer - Drug Profile 208
Small Molecules to Antagonize Androgen Receptors for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 209
Small Molecules to Inhibit Bromodomain for Prostate Cancer - Drug Profile 210
Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer - Drug Profile 211
stapuldencel-t - Drug Profile 212
TAS-3681 - Drug Profile 214
TL-118 - Drug Profile 215
TRC-105 - Drug Profile 217
Vaccine for Prostate Cancer - Drug Profile 220
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 223
vandortuzumab vedotin - Drug Profile 225
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 226
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 352
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 356
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 357
Featured News & Press Releases 357
Appendix 368
Methodology 368
Coverage 368
Secondary Research 368
Primary Research 368
Expert Panel Validation 368
Contact Us 368
Disclaimer 369

List of Tables
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2015 16
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 19
Number of Products under Development by Companies, H2 2015 (Contd...1) 20
Number of Products under Development by Companies, H2 2015 (Contd...2) 21
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Late Stage Development, H2 2015 23
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Development, H2 2015 25
Products under Development by Companies, H2 2015 26
Products under Development by Companies, H2 2015 (Contd...1) 27
Products under Development by Companies, H2 2015 (Contd...2) 28
Products under Development by Companies, H2 2015 (Contd...3) 29
Products under Development by Companies, H2 2015 (Contd...4) 30
Products under Investigation by Universities/Institutes, H2 2015 31
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H2 2015 32
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H2 2015 33
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015 34
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis, Inc., H2 2015 35
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx, Inc., H2 2015 36
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H2 2015 37
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Research Corporation, H2 2015 38
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2015 39
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2015 40
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2015 41
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015 42
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 43
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 44
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H2 2015 45
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H2 2015 46
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2015 47
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2015 48
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2015 49
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 50
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2015 51
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H2 2015 52
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 53
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2015 54
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2015 55
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 56
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2015 57
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 58
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2015 59
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2015 60
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 61
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 62
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 63
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H2 2015 64
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc., H2 2015 65
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 66
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sanofi, H2 2015 67
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H2 2015 68
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 69
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2015 70
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 71
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 72
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro, Inc., H2 2015 73
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2015 74
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 75
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H2 2015 76
Assessment by Monotherapy Products, H2 2015 77
Number of Products by Stage and Target, H2 2015 79
Number of Products by Stage and Mechanism of Action, H2 2015 83
Number of Products by Stage and Route of Administration, H2 2015 86
Number of Products by Stage and Molecule Type, H2 2015 88
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2015 231
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2015 357
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H2 2015 358
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H2 2015 359
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H2 2015 360
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2015 361

List of Figures
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2015 16
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 18
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Products, H2 2015 25
Assessment by Monotherapy Products, H2 2015 77
Number of Products by Top 10 Targets, H2 2015 78
Number of Products by Stage and Top 10 Targets, H2 2015 78
Number of Products by Top 10 Mechanism of Actions, H2 2015 82
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 82
Number of Products by Top 10 Routes of Administration, H2 2015 85
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 85
Number of Products by Top 10 Molecule Types, H2 2015 87
Number of Products by Stage and Top 10 Molecule Types, H2 2015 87

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *